A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

By C. Zarate, Jaskaran Singh, P. Carlson, N. Brutsché, R. Ameli, D. Luckenbaugh, Dennis S. Charney, Husseini K. Manji. Archives of General Psychiatry, 2006

3,423 citations recorded by the source corpus.

Subfields: Biological Psychiatry, Cellular and Molecular Neuroscience, Pharmacology

View Paper: https://www.semanticscholar.org/paper/3e83c317059846d97106b64a4befc4c24b87e3d1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biological Psychiatry

In Cellular and Molecular Neuroscience

In Pharmacology

Citations in the corpus

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial (2018, background): “At D7, the ketamine response rate ranges between 7 and 35% (Berman et al., 2000; Zarate et al., 2006; Murrough et al., 2013; Lapidus et al., 2014), while in our study 64% responded to ayahuasca.”
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression (2012, positive): “5 mg/kg) intravenous (IV) infusion (4-6).”
Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders (2012, background): “Recent evidence has suggested that ketamine, a well known anesthetic with NMDA receptor antagonist activity, is effective in very low doses for treatment of both MDD (Berman et al., 2000; Zarate et al., 2006; Price et al., 2009) and BD (Diazgranados et al., 2010).”
Glutamate NMDA receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure (2011, positive): “The results demonstrate that a single dose of ketamine produces a long-lasting (up to 7 days) increase in sucrose preference relative to CUS exposed animals (Figure 1F), a time frame comparable to that reported in clinical studies (4).”
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. (2010, positive): “The two published reports of V ketamine as a potential rapid intervention for MDD inluded IV saline as an inactive placebo control (5,6).”